Arjun Agarwal Sells 10,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the transaction, the senior vice president owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. This represents a 39.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total value of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total transaction of $128,467.65.
• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total transaction of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Trading Up 2.7%

Shares of NASDAQ:ORKA opened at $111.04 on Friday. The company has a 50 day moving average of $87.52 and a 200 day moving average of $62.61. The stock has a market cap of $7.35 billion, a P/E ratio of -54.70 and a beta of -0.34. Oruka Therapeutics, Inc. has a 12 month low of $14.08 and a 12 month high of $111.37.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ORKA. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. HC Wainwright restated a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Guggenheim restated a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Wedbush restated an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $134.30.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Oruka Therapeutics in the second quarter worth $474,916,000. Viking Global Investors LP purchased a new stake in Oruka Therapeutics during the third quarter valued at about $51,280,000. Paradigm Biocapital Advisors LP bought a new stake in Oruka Therapeutics during the fourth quarter worth about $51,840,000. Remedium Capital Partners LLC bought a new stake in Oruka Therapeutics during the fourth quarter worth about $47,054,000. Finally, Jupiter Topco LLC purchased a new position in shares of Oruka Therapeutics in the 2nd quarter worth about $130,968,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.